Ketamine Pharmacology: An Update (Pharmacodynamics and Molecular Aspects, Recent Findings)
CNS Neuroscience & Therapeutics April 10, 2013 DOI: 10.1111/cns.12099 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Ketamine Esketamine |
| Keywords | Nmda receptor Pharmacology Analgesic Opioid Anesthetic Neurotoxicity Hyperalgesia Dissociative Glutamate receptor Anesthesia Nociception |
| Citations | 690 |
| Key findings | Ketamine is a safe anesthetic with potent analgesic and antidepressive effects, acting primarily through NMDA receptor antagonism, and does not induce neurotoxicity in usual clinical practice, though chronic use is linked to cognitive disturbances and potential long-term risks in young patients. |
Abstract
For more than 50 years, ketamine has proven to be a safe anesthetic drug with potent analgesic properties. The active enantiomer is S(+)-ketamine. Ketamine is mostly metabolized in norketamine, an active metabolite. During "dissociative anesthesia", sensory inputs may reach cortical receiving areas, but fail to be perceived in some association areas. Ketamine also enhances the descending inhibiting serotoninergic pathway and exerts antidepressive effects. Analgesic effects persist for plasma concentrations ten times lower than hypnotic concentrations. Activation of the (N-Methyl-D-Aspartate [NMDA]) receptor plays a fundamental role in long-term potentiation but also in hyperalgesia and opioid-induced hyperalgesia. The antagonism of NMDA receptor is responsible for ketamine's more specific properties. Ketamine decreases the "wind up" phenomenon, and the antagonism is more important if the NMDA channel has been previously opened by the glutamate binding ("use dependence"). Experimentally, ketamine may promote neuronal apoptotic lesions but, in usual clinical practice, it does not induce neurotoxicity. The consequences of high doses, repeatedly administered, are not known. Cognitive disturbances are frequent in chronic users of ketamine, as well as frontal white matter abnormalities. Animal studies suggest that neurodegeneration is a potential long-term risk of anesthetics in neonatal and young pediatric patients.
In the evidence
This study is part of the evidence base for a synthesis in the library. Here is how each one recorded it.
-
Describes ketamine as a safe anesthetic with analgesic and antidepressant effects acting mainly through NMDA antagonism, without neurotoxicity in usual practice, but notes cognitive disturbances and frontal white matter abnormalities in chronic users and unknown consequences of repeated high doses.
Synthesized
Comparable studies
Other narrative reviews on ketamine, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms | 2018 | Review | |
| Mechanisms of Ketamine Action as an Antidepressant | 2018 | Review | |
| Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation Adults with treatment-resistant depression | 2021 | Review | |
| A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders | 2017 | Review and consensus statement | |
| Ketamine for chronic pain: risks and benefits | 2013 | Review |
Citations in the library
Cited by 133
- Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms Pharmacological Reviews June 26, 2018
- Ketamine – More mechanisms of action than just NMDA blockade Trends in Anaesthesia and Critical Care March 22, 2014
- Ketamine and Rapid-Acting Antidepressants: A Window into a New Neurobiology for Mood Disorder Therapeutics Annual Review of Medicine October 23, 2014
- Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor Molecular Psychiatry May 7, 2021
- The Role of Ketamine in Treatment-Resistant Depression: A Systematic Review Current Neuropharmacology November 12, 2014
and 128 more in the library
Cites 14
- NMDA Antagonist Neurotoxicity: Mechanism and Prevention Science December 6, 1991
- Ketamine Anesthesia & Analgesia November 1, 1998
- Rapid Resolution of Suicidal Ideation After a Single Infusion of anN-Methyl-D-Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder The Journal of Clinical Psychiatry July 13, 2010
- Use and efficacy of low-dose ketamine in the management of acute postoperative pain: a review of current techniques and outcomes Pain August 1, 1999
- Psychedelic Effects of Ketamine in Healthy Volunteers Anesthesiology 1998
and 9 more in the library